January 2010
|
-
Long-Term Impact of Efavirenz on Neuropsychological Performance and Symptoms
in
HIV-Infected Individuals (ACTG 5097s).
Clifford DB, Evans S, Yang Y, et al
HIV
Clin Trials. 2009 Jan
1;10(6):343-355.
-
Virologic Suppression, Treatment Adherence, and Improved Quality of Life on a
Once-Daily
Efavirenz-Based Regimen in Treatment-Naïve HIV-1-Infected Patients Over 96
Weeks.
Jayaweera D, Dejesus E, Nguyen KL,
et al
HIV Clin Trials. 2009
Nov-Dec;10(6):375-84
-
A WEEK-IN REVIEW FEATURED REPORT
Prospective, Randomized, Open Label Trial of Efavirenz vs Lopinavir/Ritonavir
in HIV+ Treatment-Naive Subjects With CD4+<200 cell/mm3 in Mexico.
Sierra-Madero J, Villasis-Keever A, Méndez P,et al
J Acquir Immune Defic
Syndr.
2010 Jan 20
-
A WEEK-IN REVIEW FEATURED REPORTT
he Impact of Once-Nightly Versus Twice-Daily Dosing and Baseline Beliefs
About HAART
on Adherence to Efavirenz-Based HAART Over 48 Weeks: The NOCTE Study.
Cooper V, Horne R, Gellaitry G,
et al
J Acquir Immune Defic Syndr.
2010 Jan 19
|
|
|
|
|
|
|
|
|
|
|
|
|
New and Noteworthy
Atripla
ARV
Drugs Main Page
ARV
Drugs Main Page
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader